Bioactivity and stability analysis of endostatin purified from fermentation supernatant of 293 cells transfected with Ad/rhEndo

Protein Expression and Purification

Volumn 56, Issue 2, 2007, Pages 205-211

  Liang, Zhihui ^a   Wu, Jiangxue ^a   Huang, Jialing ^a,b   Tan, Weiping ^c   Ke, Miaola ^a   Liu, Ranyi ^a   Huang, Bijun ^a   Xiao, Xia ^a   Zhao, Peng ^a   Huang, Wenlin ^a,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Adenovirus vector; Bioactivity; Endostatin; Purification; Stability

Indexed keywords

ENDOSTATIN; RECOMBINANT PROTEIN;

ADENOVIRUS; ARTICLE; CELL CULTURE; CELL MIGRATION ASSAY; CELL PROLIFERATION; FERMENTATION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; TUMOR CELL LINE;

ADENOVIRIDAE; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL PROLIFERATION; CELLS, CULTURED; ENDOSTATINS; FERMENTATION; GENETIC VECTORS; HUMANS; RECOMBINANT PROTEINS; TRANSFECTION;

ADENOVIRIDAE;

EID: 35448950021     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2007.08.008     Document Type: Article

References (19)

1. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
2. Folkman J. Endogenous angiogenesis inhibitors. APMIS 112 (2004) 496-507
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (2002) 5-18
4. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
5. Sasaki T., Larsson H., Kreuger J., Salmivirta M., Claesson-Welsh L., Lindahl U., Hohenester E., and Timpl R. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 18 (1999) 6240-6248
6. Dhanabal M., Volk R., Ramchandran R., Simons M., and Sukhatme V.P. Cloning, expression and in vitro activity of human endostatin. Biochem. Biophys. Res. Commun. 258 (1999) 345-352
7. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
8. Folkman J. Clinical application of research on antiangiogensis. N. Engl. J. Med. 333 (1995) 1757-1763
9. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
10. Herbst R.S., Lee A.T., Tran H.T., and Abbruzzese J.L. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr. Oncol. Rep. 3 (2001) 131-140
11. Eder Jr. J.P., Supko J.G., Clark J.W., Puchalski T.A., Garcia-Carbonero R., Ryan D.P., Shulman L.N., Proper J., Kirvan M., Rattner B., Connors S., Keogan M.T., Janicek M.J., Fogler W.E., Schnipper L., Kinchla N., Sidor C., Phillips E., Folkman J., and Kufe D.W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 20 (2002) 3772-3784
12. Sun Y., Wang J., Liu Y., Song X., Zhang Y., Li K., Zhu Y., Zhou Q., You L., and Yao C. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. (2005) 23
13. Crystal R.G. The body as a manufacturer of endostatin. Nat. Biotechnol. 17 (1999) 336-337
14. Sauter B.V., Martinet O., Zhang W.J., Mandeli J., and Woo S.L. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA 97 (2000) 4802-4807
15. Blezinger P., Wang J.J., Gondo M., Quezada A., Mehrens D., French M., Singhal A., Sullivan S., Rolland A., Ralston R., and Min W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17 (1999) 343-348
16. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312 (2006) 594-607
17. Li L., Liu R.Y., Huang J.L., Liu Q.C., Li Y., Wu P.H., Zeng Y.X., and Huang W. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int. J. Cancer. 118 (2006) 2064-2071
18. Liang Z.H., Wu P.H., Li L., Xue G., Zeng Y.X., and Huang W.L. Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recombinant endostatin protein. Chin. Med. J. (Engl.) 117 (2004) 1809-1814
19. Lin X.B., Huang H.Q., Li S., Li H.L., Li Y.H., Cao Y., Zhang D.S., Xia Y.F., Guo Y., Huang W.L., and Jiang W.Q. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol. Ther. 6 (2007)